Anzeige
Mehr »
Donnerstag, 31.07.2025 - Börsentäglich über 12.000 News
Der KI-Energiekollaps: Uran auf kritischem Kurs - und Foremost Clean Energy entflammt den Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XE7A | ISIN: CA4990531069 | Ticker-Symbol: 04K
Tradegate
30.07.25 | 16:31
3,960 Euro
+2,06 % +0,080
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KNIGHT THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
KNIGHT THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,7803,84016:50
3,8203,84016:49

Aktuelle News zur KNIGHT THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
18.07.Knight Therapeutics Inc: Knight files new drug submission for Crexont in Canada2
KNIGHT THERAPEUTICS Aktie jetzt für 0€ handeln
18.07.Stocks in Play: Knight Therapeutics Inc.-
18.07.Knight Therapeutics Announces Filing of New Drug Submission for CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Canada170MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission...
► Artikel lesen
18.06.Knight Therapeutics Inc: Knight Therapeutics closes Paladin acquisition1
17.06.Knight Therapeutics Inc: Knight secures $50M (U.S.) revolving credit facility2
17.06.Stocks in Play: Knight Therapeutics Inc.1
17.06.Knight Therapeutics Announces Closing of Previously Announced Acquisition of Paladin204MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition...
► Artikel lesen
17.06.Knight Therapeutics: Knight Closes US$50 Million Revolving Credit Facility with NBC2
05.06.Is Knight Therapeutics stock a buy?1
05.06.Stocks in Play: Knight Therapeutics Inc.-
05.06.Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo's Canadian Portfolio229MONTREAL and MARLBOROUGH, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, and Sumitomo Pharma America...
► Artikel lesen
13.05.Stocks in Play: Knight Therapeutics Inc2
09.05.Knight Therapeutics is a buy, Stifel says2
08.05.Stocks in Play: Knight Therapeutics Inc.3
08.05.Knight Therapeutics reports Q1 results1
08.05.Knight Therapeutics Inc: Knight Therapeutics shareholders elect seven directors1
07.05.Knight Therapeutics Inc. announces voting results from the Annual General Meeting91MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) specialty pharmaceutical company, announced today the voting results...
► Artikel lesen
07.05.Knight Therapeutics Inc: Knight Therapeutics to re-release Onicit IV2
07.05.Knight Therapeutics Announces Relaunch of ONICIT in Brazil and Mexico3
01.05.Knight Therapeutics Inc: Knight Therapeutics to release Q1 2025 results May 81
Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1